6月11日，葛兰素史克盘中上涨3.06%，报52.9美元/股，成交额1.52亿美元。
消息面上，GSK近日宣布以106亿美元（每股124美元）现金收购美国肿瘤药企Nuvalent，较后者收盘价溢价约40%，为公司史上最大规模收购。Nuvalent旗下两款针对ALK及ROS1阳性非小细胞肺癌的药物均已进入后期临床阶段，FDA预计今年内作出审批决定。GSK表示该交易不影响全年业绩指引，预计自2027年起贡献收入增长，并在2028至2030年核心产品专利到期期间强化盈利能力。此外，GSK乙肝功能性治愈新药三期数据积极，中国上市申请已获优先审评受理，多重管线进展共同支撑股价表现。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.